Gilead Sciences vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Gilead Sciences is more profitable. Merck & grows faster, is cheaper for its profits and has less debt.
Side by side
| Gilead Sciences | Merck & | |
|---|---|---|
| $208 billion | $364 billion | |
| 28.9% | 28.1% | |
| +3.6% | +9.4% | |
| 24.5× | 20.0× | |
| 1.3 years | 1.2 years | |
| 18.4% | 17.8% | |
| 2.3% | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Gilead Sciences vs Roche · Gilead Sciences vs Revolution Medicines · Gilead Sciences vs UnitedHealth · Gilead Sciences vs AbbVie · Merck & vs Intuitive Surgical · Merck & vs Johnson & Johnson · Merck & vs Eli Lilly · Merck & vs McKesson